

The evidence you cant ignore.

Wilate now approved for prophylaxis in Canada

WIL-31 study confirms Wilate[®] prophylaxis in reducing bleeding in VWD patients

The WIL-31 study is a significant prospective prophylaxis study on von Willebrand disease (VWD), the largest of its kind. It uniquely includes a prospective on-demand run-in as an intra-individual comparator. The study demonstrates that prophylaxis with Wilate[®], a von Willebrand factor/factor VIII (VWF/FVIII) concentrate, is highly effective in reducing bleeding rates in both children and adults with all types of VWD compared to previous on-demand treatment.


Octapharma announced these results, which were published in Blood Advances by Sidonio RF Jr et al., under the title "Von Willebrand factor/factor VIII concentrate (Wilate[®]) prophylaxis in children and adults with von Willebrand disease."

The study included a diverse patient population, covering young children and adults of both genders and all types of VWD.

The findings support the use of VWF prophylaxis and have led to the addition of Wilate[®] prophylaxis as a therapeutic indication for VWD in the US, thereby increasing access for the patient population.

VWD is a serious challenge for paediatric populations

Difficult diagnosis



Paediatric-specific VWD bleeding phenotype such as epistaxis, bruising, and oropharyngeal bleeding is common in children without VWD¹

Severe bleeding



Following surgery, dental procedures and trauma¹

Impact on HRQoL



Bleeding symptoms result in decreased HRQoL for children and their caregivers^{2,3}


Prophylaxis in children reduces the frequency of recurrent bleeds and may also prevent joint damage^{4,5}

HRQoL: Health related quality of life.

1. Sanders YV et al. *Am J Hematol* 2015; 90:1142-8; 2. Olsson A et al. *Haemophilia* 2023; 29:1056-62; 3. de Wee EM et al. *J Thromb Haemost* 2011; 9:502-9; 4. Berntorp and Petrini P. *Blood Coagul Fibrinolysis* 2005; 16 Suppl 1:S23-6; 5. Halimeh S et al. *Thromb Haemost* 2011; 105:597-604.

For full prescribing information, please refer to the product monograph.

WIL-31: Demographics of children and adolescent population




Characteristic median (range) unless otherwise specified	Children 6–11 years old (n = 9)	Adolescents 12–16 years old (n = 6)
VWD type, n (%)		
Type 1	2 (22)	1 (17)
Type 2A	2 (22)	1 (17)
Type 3	5 (56)	4 (66)
Age, years	9 (7–11)	15 (12–16)
Height, cm	136 (118–146)	165 (151–182)
Weight, kg	28 (21–41)	67 (40–92)
Caucasian, n (%)	9 (100)	6 (100)
Blood type, n (%)		
A	7 (78)	2 (33)
B	1 (11)	1 (17)
AB	1 (11)	0 (0)
O	0 (0)	3 (50)
Family history of VWD, n (%)	4 (44)	4 (67)

Octapharma, data on file.

For full prescribing information, please refer to the product monograph.

WIL-31: Prophylaxis with wilate[®] reduced ABRs in children and adolescent patients

Reduction in total and spontaneous ABR during on-demand treatment and prophylaxis




SD: standard deviation.
Octapharma, data on file.

For full prescribing information, please refer to the product monograph.

WIL-31: wilate[®] prophylaxis reduced bleeding in children and adolescents


Location of bleeding sites during wilate[®] prophylaxis



* Other bleeds include cutaneous, head, hip, and toe. † Other bleeds include cutaneous and tonsil. Octapharma, data on file.


WIL-31: Prophylaxis with wilate[®] reduced the number and severity of bleeds in children and adolescent patients

Patient bleeding during prophylaxis



100% of children and adolescents experienced bleeding during on-demand treatment

Bleed severity*




*Excluding menstrual bleeds.

Octapharma, data on file.

For full prescribing information, please refer to the product monograph.

WIL-31: wilate[®] prophylaxis substantially reduced joint bleeding in children and adolescents

Reduction in total ABR between on-demand treatment and prophylaxis



Children experienced no joint bleeds during prophylaxis
Adolescents experienced substantial reductions in knee and ankle joint bleeds

Octapharma, data on file.
 For full prescribing information, please refer to the product monograph.